主页 > 医学讨论 >
【文摘发布】血清HBV RNA可早期预测拉米夫定治疗
Authors:Hatakeyama T, Noguchi C, Hiraga N, Mori N, Tsuge M, Imamura M, Takahashi S, Kawakami Y, Fujimoto Y, Ochi H, Abe H, Maekawa T, Kawakami H, Yatsuji H, Aisaka Y, Kohno H, Aimitsu S, Chayama K.
Resource: Hepatology. 2007 May;45(5):1179-86
Abstract:
Lamivudine (LAM) is a nucleoside analogue widely used for the treatment of chronic hepatitis B virus (HBV) infection. Emergence of resistant strains with amino acid substitutions in the tyrosine-methionine-aspartate-aspartate (YMDD) motif of reverse transcriptase is a serious problem in patients on LAM therapy. The amount of covalently closed circular DNA in the serum is reported to be higher in patients who develop YMDD mutants than in those without mutants. However, there is no useful serum marker that can predict early emergence of mutants during LAM therapy. Analysis of patients who were treated with entecavir (n = 7) and LAM (n = 36) showed some patients had high serum levels of HBV RNA. Median serum levels of HBV RNA were significantly higher in patients in whom the YMDD mutant had emerged within 1 year (n = 6, 1.688 log copies/ml) than in those in whom the YMDD mutant emerged more than 1 year after treatment (n = 12, 0.456 log copies/ml, P = 0.0125) or in whom the YMDD mutant never emerged (n = 18, 0.688 log copies/ml, P = 0.039). Our results suggest that HBV RNA is a valuable predictor of early occurrence of viral mutation during LAM therapy. (HEPATOLOGY 2007;45:1179-1186.).
PMID: 17465002
注：YMDD——酪氨酸-蛋氨酸-天冬氨酸-天冬氨酸(Tyrosine-Methionine-Aspartic acid-Aspartie acid,YMDD) 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领。 Title:Serum HBV RNA is a predictor of early emergence of the YMDD mutant in patients treated with lamivudine.
题目：血清HBV RNA可早期预测拉米夫定治疗后出现的YMDD变异
Authors:Hatakeyama T, Noguchi C, Hiraga N, Mori N, Tsuge M, Imamura M, Takahashi S, Kawakami Y, Fujimoto Y, Ochi H, Abe H, Maekawa T, Kawakami H, Yatsuji H, Aisaka Y, Kohno H, Aimitsu S, Chayama K.
作者：Hatakeyama T, Noguchi C, Hiraga N, Mori N, Tsuge M, Imamura M, Takahashi S, Kawakami Y, Fujimoto Y, Ochi H, Abe H, Maekawa T, Kawakami H, Yatsuji H, Aisaka Y, Kohno H, Aimitsu S, Chayama K.
Resource: Hepatology. 2007 May;45(5):1179-86
来源：《肝脏病学》. 2007 May;45(5):1179-86
Abstract:摘要
Lamivudine (LAM) is a nucleoside analogue widely used for the treatment of chronic hepatitis B virus (HBV) infection.
拉米夫定是一种核苷类似物，被广泛应用于治疗慢性乙肝。
Emergence of resistant strains with amino acid substitutions in the tyrosine-methionine-aspartate-aspartate (YMDD) motif of reverse transcriptase is a serious problem in patients on LAM therapy.
逆转录过程中的酪氨酸-蛋氨酸-天冬氨酸-天冬氨酸（YMDD）模序中的氨基酸发生代替会产生耐药菌侏，这是接受拉米夫定治疗的病人面对的一个严重问题。
The amount of covalently closed circular DNA in the serum is reported to be higher in patients who develop YMDD mutants than in those without mutants.
据报道，血清中共价闭合环状DNA的水平在发生YMDD变异的病人中要比不发生变异的病人高。
However, there is no useful serum marker that can predict early emergence of mutants during LAM therapy.
然而，在拉米夫定的治疗过程中，并没有有效的血清标志物能预测变异的早期发生。
Analysis of patients who were treated with entecavir (n = 7) and LAM (n = 36) showed some patients had high serum levels of HBV RNA.
对接受恩替卡韦（entecavir）（7例）和接受拉米夫定（36例）治疗的病人进行分析发现：一些病人血清中的HBV RNA处于高水平。
Median serum levels of HBV RNA were significantly higher in patients in whom the YMDD mutant had emerged within 1 year (n = 6, 1.688 log copies/ml) than in those in whom the YMDD mutant emerged more than 1 year after treatment (n = 12, 0.456 log copies/ml, P = 0.0125) or in whom the YMDD mutant never emerged (n = 18, 0.688 log copies/ml, P = 0.039).
在一年内发生YMDD变异的病人（n=6，1.688 log copies/ml）的血清HBV RNA水平的中位数显著高于接受治疗一年后发生YMDD变异的病人（n=12，0.456 log copies/ml，P=0.0125）或从没发生过YMDD变异的病人（n=18，0.688 log copies/ml，P=0.039）。
Our results suggest that HBV RNA is a valuable predictor of early occurrence of viral mutation during LAM therapy. (HEPATOLOGY 2007;45:1179-1186.).
我们的研究结果表明：在拉米夫定治疗过程中，HBV RNA的水平是一个有价值的预测病毒变异的预测因子。（肝脏病学 2007;45:1179-1186）
PMID: 17465002
编译投稿：
共401字
【据《肝脏病学》2007年5月报道】题：血清HBV RNA可早期预测拉米夫定治疗后出现的YMDD变异 （作者 Hatakeyama等）
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-05-28 17:11
医学,生命科学网